Logos Global Management LP Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001792126

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidHealth TiltHigh Turnover how tags are computed

Q2 2026 · 68 positions · Total reported value $2.32B · Top-10 concentration 48.3% · Updated 2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

Turnover: 72.7% · 25 new · 19 cut · 20 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +22.9% · vs SPY +8.1% · Prev Value $1.89B — last quarter positions weighted by this quarter price moves · ranking

In its Q2 2026 13F filing, Logos Global Management LP disclosed 68 equity positions with a combined reported value of $2.32B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 48.3% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2026 were ERAS ($222.59M), ABVX ($136.46M), RVMD ($131.10M). By sector, the heaviest allocations are Health Care 99.1%, Financials 0.1%. Versus the prior quarter, allocation shifted toward Health Care (+5.5pp) and away from Other (-5.6pp).

Versus the prior quarter, Logos Global Management LP opened 25 new positions, trimmed 19 and fully exited 20, a turnover rate of 72.7% of positions. The portfolio's overlap with the prior quarter was 49% of names.

The largest new positions opened in Q2 2026 were BNTX ($94.45M), VERA ($94.40M), BLTE ($38.50M).

Of the 20 positions fully exited versus the prior quarter, the largest were CNTA ($84.41M), CYTK ($57.67M), UTHR ($47.44M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2026)

  • BNTX BIONTECH SE · $94.45M
  • VERA VERA THERAPEUTICS INC · $94.40M
  • BLTE BELITE BIO INC F · $38.50M
  • ACHV ACHIEVE LIFE SCIENCES INC · $35.43M
  • COGT COGENT BIOSCIENCES INC · $34.83M
  • CMPS COMPASS PATHWAYS · $31.84M
  • MLYS MINERALYS THERAPEUTICS INC · $28.33M
  • REPL REPLIMUNE GROUP INC · $27.68M

Fully Exited (vs previous quarter)

  • CNTA CENTESSA PHARMACEUTICALS PLC · prev qtr: $84.41M
  • CYTK CYTOKINETICS INC · prev qtr: $57.67M
  • UTHR UNITED THERAPEUTICS CORP DEL COM · prev qtr: $47.44M
  • MDGL MADRIGAL PHARMACEUTICALS INC · prev qtr: $44.49M
  • BIIB BIOGEN INC COM · prev qtr: $36.67M
  • TYRA TYRA BIOSCIENCES INC · prev qtr: $32.55M
  • TERN TERNS PHARMACEUTICALS INC · prev qtr: $26.36M
  • NAMS NEWAMSTERDAM PHARMA COMPANY · prev qtr: $19.21M

Insider Transactions (Form 4)

Latest Logos Global Management LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Logos Global Management LP is an SEC-registered 13F filer based in San Francisco, CA, United States. As of Q2 2026 it reported 68 US equity positions with a combined value of $2.32B. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: SAN FRANCISCO, CA, United States
  • SEC registration: 801-117248 (status: Approved), registered 2019-08-26
  • Regulatory AUM (Form ADV): $2.25B as of 2026-04-22
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 5 private funds, of which 1 hedge funds

Portfolio Structure

  • 68 positions · $2.32B reported value (Q2 2026)
  • Top 10 holdings = 48.3% of reported value
  • Largest position: ERAS (ERASCA INC COM) at 9.6%
  • Average position size: $34.16M

Sector Tilt

  • Health Care 99.1%
  • Financials 0.1%
  • (classified holdings cover 99% of value)

Quarterly Activity

  • Q2 2026: 25 new, 18 added, 19 reduced, 20 exited
  • 6 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 99.1%
Financials 0.1%
Other 0.8%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 12.15M $222.59M 9.58%
9.58%
Add
2 1.02M $136.46M 5.87%
5.87%
Add
3 700.00K $131.10M 5.64%
5.64%
Reduce
4 3.00M $111.81M 4.81%
4.81%
Reduce
5 1.01M $94.45M 4.07%
4.07%
New
6 2.20M $94.40M 4.06%
4.06%
New
7 2.85M $89.09M 3.83%
3.83%
Reduce
8 260.00K $87.05M 3.75%
3.75%
Reduce
9 2.10M $78.14M 3.36%
3.36%
Add
10 800.00K $77.98M 3.36%
3.36%
Add
11 1.00M $71.05M 3.06%
3.06%
Add
12 875.00K $64.00M 2.75%
2.75%
Add
13 1.94M $57.74M 2.49%
2.49%
Add
14 2.55M $56.64M 2.44%
2.44%
Add
15 2.67M $52.08M 2.24%
2.24%
Add
16 5.30M $52.05M 2.24%
2.24%
Add
17 3.00M $43.41M 1.87%
1.87%
Add
18 3.21M $40.14M 1.73%
1.73%
Hold
19 250.00K $38.50M 1.66%
1.66%
New
20 5.42M $35.43M 1.52%
1.52%
New
21 1.88M $35.06M 1.51%
1.51%
Reduce
22 900.00K $34.83M 1.50%
1.50%
New
23 1.00M $34.74M 1.50%
1.50%
Add
24 1.90M $34.20M 1.47%
1.47%
Add
25 2.25M $31.84M 1.37%
1.37%
New
26 1.05M $28.33M 1.22%
1.22%
New
27 2.50M $27.68M 1.19%
1.19%
New
28 450.00K $27.16M 1.17%
1.17%
Hold
29 500.00K $26.84M 1.16%
1.16%
Hold
30 665.00K $25.62M 1.10%
1.10%
Reduce
31 1.12M $25.00M 1.08%
1.08%
Add
32 465.00K $23.60M 1.02%
1.02%
Reduce
33 180.00K $22.13M 0.95%
0.95%
Add
34 1.15M $21.25M 0.92%
0.92%
Add
35 650.00K $20.04M 0.86%
0.86%
Reduce
36 1.35M $19.67M 0.85%
0.85%
New
37 600.00K $19.05M 0.82%
0.82%
Reduce
38 585.00K $18.99M 0.82%
0.82%
Reduce
39 3.29M $18.25M 0.79%
0.79%
Add
40 722.02K $18.05M 0.78%
0.78%
Add
41 300.00K $16.36M 0.70%
0.70%
New
42 915.00K $15.01M 0.65%
0.65%
New
43 525.00K $14.37M 0.62%
0.62%
New
44 125.00K $13.88M 0.60%
0.60%
Reduce
45 650.00K $11.97M 0.52%
0.52%
Reduce
46 200.00K $11.00M 0.47%
0.47%
New
47 1.00M $10.31M 0.44%
0.44%
Reduce
48 800.00K $10.19M 0.44%
0.44%
New
49 521.74K $9.76M 0.42%
0.42%
New
50 1.50M $8.56M 0.37%
0.37%
New

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q3) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q2)

P 60% R 60% F1 60% (modelled on 2026-Q1; 6/10 hit)

Low-confidence forecast This fund replaces about 49% of its Top-10 each quarter and backtests at F1 47% (threshold 80%). Holdings in high-turnover portfolios cannot be forecast from their own history; the figures below are illustrative.

Historical Backtest (10 quarters)

Avg precision 47% · recall 47% · F1 47% · avg rank error 4.0 · Top-10 turnover 49%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2024-Q1 60% 60% 60% CYTK · SRPT · APLS · IDYA · OLMA · ARGX · GPCR · IMVT · RYZB · RCKT ALNY · IDYA · IMCR · IMVT · OCUL · SRPT · OLMA · DYN · APLS · RCKT
2024-Q2 30% 30% 30% ALNY · IMCR · IDYA · IMVT · SRPT · OCUL · OLMA · APLS · DYN · SLN XBI · IDYA · ARGX · MRUS · RVMD · IRON · OCUL · OLMA · VERA · MLTX
2024-Q3 50% 50% 50% XBI · IDYA · ARGX · MRUS · RVMD · IRON · VERA · MLTX · OCUL · JANX IDYA · GPCR · RVMD · IRON · JANX · OLMA · PCVX · IMVT · CLDX · OCUL
2024-Q4 40% 40% 40% IDYA · GPCR · RVMD · JANX · IRON · OLMA · PCVX · IONS · ERAS · CLDX IDYA · JANX · RVMD · CYTK · VERA · BNTX · MRUS · ERAS · INSM · OCUL
2025-Q1 40% 40% 40% IDYA · JANX · RVMD · CYTK · VERA · ERAS · BNTX · MRUS · INSM · NBIX IDYA · RVMD · AKRO · JANX · NUVL · TEVA · XENE · KROS · IRON · BNTX
2025-Q2 50% 50% 50% IDYA · RVMD · AKRO · JANX · NUVL · TEVA · XENE · ETNB · KROS · SLNO XBI · IDYA · AKRO · RVMD · JAZZ · IRON · RNAM · KROS · TEVA · BIIB
2025-Q3 20% 20% 20% XBI · IDYA · AKRO · RVMD · JAZZ · IRON · RNAM · KROS · BIIB · TEVA AKRO · ARVN · RVMD · OCUL · CDTX · VSTM · ABVX · ERAS · MAZE · OLMA
2025-Q4 60% 60% 60% AKRO · ARVN · RVMD · CDTX · VSTM · OCUL · MAZE · ABVX · DYN · ERAS PRAX · OLMA · RVMD · CDTX · ABVX · ERAS · OCUL · GPCR · IRON · MAZE
2026-Q1 60% 60% 60% PRAX · OLMA · RVMD · CDTX · ABVX · ERAS · OCUL · MAZE · TNGX · GPCR RVMD · ERAS · IDYA · PRAX · CNTA · ABVX · TNGX · CYTK · OLMA · UTHR
2026-Q2 ★ 60% 60% 60% RVMD · ERAS · IDYA · PRAX · CNTA · ABVX · TNGX · CYTK · MDGL · IMCR ERAS · ABVX · RVMD · IDYA · BNTX · VERA · TNGX · PRAX · CLDX · DNTH

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

FAQ

What did Logos Global Management LP buy in 2026-Q2?

In its 2026-Q2 13F filing, Logos Global Management LP reported 68 equity positions worth $2.32B in aggregate; its largest disclosed positions were ERAS ($222.59M), ABVX ($136.46M), RVMD ($131.10M).

How large is Logos Global Management LP's portfolio?

Logos Global Management LP reported $2.32B of long equity holdings across 68 positions as of 2026-Q2. Top-10 holdings account for 48.3% of reported value.

What is Logos Global Management LP's investment style?

HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/logos-global-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →